title: Effect of LY294002 on adriamycin-induced epithelial-mesenchymal transition in human breast carcinoma cells.
abstract: OBJECTIVE
  To study the effect of LY294002 on the adriamycin- induced epithelial-mesenchymal transition in human breast carcinoma cells.
  
  
  METHODS
  Human breast carcinoma cells MCF-7 was cultured in vitro and then exposed to adriamycin with or without LY294002. The protein expression levels of Akt, phosphorylated-Akt (p-Akt), Snail, and E-cadherin was detected by Western blot analysis. The mRNA expressions of Snail and E-cadherin were determined by RT-PCR.
  
  
  RESULTS
  Adriamycin significantly increased the protein expression of Snail and depressed the protein expression of E-cadherin (P<0.05). The pre-treatment with LY294002 significantly reversed the changes of activities and levels of the above proteins (P<0.05).
  
  
  CONCLUSIONS
  LY294002 could reverse the adriamycin-induced epithelial-mesenchymal transition in human breast carcinoma cells by regulating the expressions of Snail and E-cadherin through suppressing PI3K/Akt signaling pathway.
authors.affiliation: Nanjing Medical University, Nanjing, China.
authors.forename: Yu-jun
authors.initials: YJ
authors.lastname: Qian
authors.forename: Xiang-ming
authors.initials: XM
authors.lastname: Cheng
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Xu
authors.forename: Chen-jiang
authors.initials: CJ
authors.lastname: Wu
authors.forename: Meng-lin
authors.initials: ML
authors.lastname: Zhao
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Qi
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
mesh_terms: D015703:Antigens, CD; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D015820:Cadherins / Q000378:metabolism; D002867:Chromones / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D006801:Humans; D061986:MCF-7 Cells; D009025:Morpholines / Q000494:pharmacology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D000071250:Snail Family Transcription Factors; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C513384:CDH1 protein, human; D015820:Cadherins; D002867:Chromones; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000071250:Snail Family Transcription Factors; D014157:Transcription Factors; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D004317:Doxorubicin; D051057:Proto-Oncogene Proteins c-akt